13F Holdings
中文EN

IDYA IDEAYA Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1676725 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-70.1%
TTM net income YoY-143.0%
TTM EPS YoY-71.4%
Revenue 3-yr CAGR-37.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,671.1%
Net margin-3,921.1%
FCF margin-3,592.0%
EBITDA margin-4,637.0%

Returns

ROE-32.7%
ROA-31.0%
ROIC (approx.)-35.9%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets5.8%
Debt / equity0.00x
Current ratio14.97x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-3.0%
Payout ratio—
Capex / revenue55.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.24M$8.86M$6.56M$10.88M$207.83M——$7.00M
R&D expense$121.58M$82.99M$95.73M$86.60M$82.99M$74.23M$70.89M$140.18M
SG&A expense$26.30M$22.46M$19.38M$18.85M$16.39M$14.58M$13.50M$10.96M
Operating income-$137.63M-$122.29M-$108.54M-$94.57M$108.45M-$88.81M-$84.39M-$144.14M
Income tax$0$0$0$0$0$0$0$0
Net income-$125.75M-$112.45M-$98.54M-$83.27M$119.24M-$77.49M-$72.18M-$130.31M
EBITDA-$136.93M-$121.59M-$107.86M-$93.85M$109.15M-$88.11M-$83.79M-$143.57M
EPS (basic)-1.22-1.22-1.11—1.35-0.88-0.82—
EPS (diluted)-1.22-1.22-1.11—1.33-0.88-0.82—
Weighted avg. shares (diluted)102.94M92.06M88.70M—89.69M88.47M88.36M—
Balance sheet
Cash & equivalents$261.45M$272.59M$157.52M$112.83M$298.93M$114.64M$130.00M$85.18M
Short-term investments$577.09M$556.37M$513.68M$526.56M$487.97M$555.09M$562.51M$591.94M
Receivables———————$3,000
Current assets$871.97M$864.02M$696.11M$666.73M$802.65M$685.60M$707.87M$689.71M
PP&E, net$7.94M$8.28M$8.63M$8.22M$8.17M$8.82M$8.87M$8.97M
Total assets$1.22B$1.31B$1.03B$1.11B$1.19B$1.04B$1.10B$1.12B
Current liabilities$96.41M$82.68M$64.83M$58.81M$64.51M$55.34M$50.85M$46.07M
Total liabilities$123.96M$110.79M$93.08M$86.39M$93.10M$81.62M$76.51M$64.94M
Shareholders' equity$1.09B$1.20B$937.27M$1.02B$1.09B$959.65M$1.02B$1.06B
Shares outstanding96.65M96.38M87.86M87.80M87.67M87.64M87.57M86.50M
Cash flow statement
Operating cash flow-$93.48M-$88.21M-$75.17M-$90.50M$142.21M-$62.47M-$60.34M-$121.66M
Capital expenditure$273,000$866,000$967,000$333,000$42,000$663,000$1.33M$1.10M
Free cash flow-$93.75M-$89.08M-$76.14M-$90.83M$142.17M-$63.14M-$61.67M-$122.76M
Investing cash flow$78.65M-$155.93M$118.95M-$97.53M$41.77M$45.92M$79.82M-$197.11M
Financing cash flow$3.69M$359.21M$1.18M$2.13M$301,000$1.21M$26.14M$2.75M
Depreciation & amortization$700,000$700,000$688,000$721,000$700,000$700,000$600,000$572,000
Stock-based compensation$17.73M$16.66M$14.54M$11.79M$12.22M$11.87M$10.24M$9.48M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.